Skip to main content
. Author manuscript; available in PMC: 2019 Nov 1.
Published in final edited form as: Pigment Cell Melanoma Res. 2018 Jun 28;31(6):708–719. doi: 10.1111/pcmr.12712

Fig. 3. Combined viSNE analysis of melanoma tumors identifies patient specific changes in tumor phenotype following BRAF and MEK inhibitor treatment.

Fig. 3

(A) viSNE density plots show phenotype and abundance of melanoma cells from paired samples of Pre-Tx and Week 4 tumors (N = 7 tumors). A combination viSNE density plot (upper left) shows all patients combined in two plots at Pre-Tx and Week 4. (B) FlowSOM cluster analysis of all patients (Pre-tx and Week 4 combined, as in A) automatically identified phenotypically distinct subsets. (C) Abundance (% of Pre-Tx or % of Week 4 cells) for all subsets identified by FlowSOM is shown, organized from least to most common in Pre-Tx or Week 4 melanoma tumors. Subset labels from (B) and (C) are the same and additional information on patients and subset phenotypes is shown in Supplementary Table S4 and Supplementary Figure S5.